Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.39 |
| ▸ | SCN4A | P35499 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12558063 | 1.00 | NPC1 (0.45) | NPC1SMN1; SMN2LMNANPSR1KMT2A | |
| SCHEMBL8276961 | 0.90 | KMT2A (0.48) | NPC1SMN1; SMN2LMNANPSR1KMT2A | |
| SCHEMBL8221989 | 0.90 | KMT2A (0.48) | NPC1SMN1; SMN2LMNANPSR1KMT2A | |
| SCHEMBL1646270 | 0.90 | KMT2A (0.48) | NPC1SMN1; SMN2LMNANPSR1KMT2A | |
| SCHEMBL8244195 | 0.90 | KMT2A (0.48) | NPC1SMN1; SMN2LMNANPSR1KMT2A | |
| SCHEMBL1683094 | 0.90 | KMT2A (0.48) | NPC1SMN1; SMN2LMNANPSR1KMT2A | |
| SCHEMBL13787351 | 0.90 | KMT2A (0.48) | NPC1SMN1; SMN2LMNANPSR1KMT2A | |
| SCHEMBL15672689 | 0.83 | SMN1; SMN2 (0.41) | NPC1SMN1; SMN2LMNANPSR1KMT2A | |
| SCHEMBL4793431 | 0.83 | — | — | |
| SCHEMBL12820010 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011150190-A2 | HCV INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ANACOR PHARMACEUTICALS, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| US-7939667-B2 | Hepatitis C inhibitor compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-10 | — | — | US | disclosed |
| EP-1654261-B1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2007-11-14 | — | — | EP | disclosed |
| US-20070243166-A1 | Hepatitis C Inhibitor Compounds | LLINAS-BRUNET MONTSE | 2007-10-18 | — | — | US | disclosed |
| WO-2004103996-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070243166-A1 | Hepatitis C Inhibitor Compounds | HAVCR2, CTRL, CTRC | NPC1 150/4885SMN1; SMN2 4624/4885LMNA 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.